Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D06QXI
|
||||
| Former ID |
DIB012230
|
||||
| Drug Name |
NRX-4204
|
||||
| Synonyms |
AGN-190205; AGN-191183; AGN-191659; AGN-191701; AGN-192326; AGN-192327; AGN-192509; AGN-192599; AGN-192870; AGN-194204; AGN-194277; AGN-195393; AGN-4202; ALRT-326; ALRT-4204; LGD-4204; LGD-4326; NRX-194202; NRX-194204; RXR ligands, ALRT; RXR ligands, Allergan; Retinoid X receptor agonists, ALRT; Retinoid X receptor agonists, Allergan; VTP-4204; RXR agonists, Allergan/Pfizer; Rexinoid receptor agonist (cancer), NuRx; RXR agonists (cancer/ diabetes), Vitae Pharmaceuticals; RXR agonists, Allergan/Parke-Davis
|
||||
| Drug Type |
Small molecular drug
|
||||
| Company |
Allergan Ligand Retinoid Therapeutics Inc
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C24H32O2
|
||||
| InChI |
InChI=1S/C24H32O2/c1-16(13-21(25)26)7-8-18-15-24(18,6)17-9-10-19-20(14-17)23(4,5)12-11-22(19,2)3/h7-10,13-14,18H,11-12,15H2,1-6H3,(H,25,26)/b8-7+,16-13+
|
||||
| InChIKey |
BOOOLEGQBVUTKC-YWRSBGDESA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Retinoic acid receptor RXR-gamma | Target Info | Modulator | ||
| References | |||||
| Ref 523805 | ClinicalTrials.gov (NCT01540071) Trial of NRX 194204 in Castration- and Taxane-Resistant Prostate Cancer. U.S. National Institutes of Health. | ||||
| Ref 539853 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2811). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.